e-therapeutics teams up with a top-five pharma company for neurodegenerative diseases project
The 12-month tie-up with the unnamed drug giant will showcase the research group's network-driven drug discovery approach
Sector
Health
1063 stories · page 51 of 54
VolitionRx balance sheet strengthens in second quarter with cash increasing significantly
The Belgium-based firm said its cash and cash equivalents as of June 30, 2019 totaled $18.5 million compared to $13.4 million as of the end of 2018
Biocept shares rise after reporting revenue boost in 2Q
The firm said growth was driven by a 26% year-over-year increase in commercial samples as it focused on segments of the liquid biopsy oncology market
Callitas Health capitalizes on CannaStrips, OTC goods while swinging for the fence with blockbuster drugs
Callitas Health Inc CEO James Thompson says the company has 'a lot of irons in the fire that should come to fruition over the next few months'
Orgenesis Inc sees record fiscal 2Q revenue beat estimates
The company saw its revenue shoot up by 95% to $7.8 million, which easily beat the consensus estimate of $6.4 million
NA Proactive news snapshot: Biocept, Orgenesis, Ipsidy, VolitionRx UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor
The drug developer also recently raised £2.66mln from its institutional investor, Lanstead Capital, to help execute its corporate strategy
Propanc Biopharma publishes promising study of its metastatic cancer drug in peer-reviewed medical journal
The study confirmed the effects its drug against cancer stem cells within tumors that are capable of self-renewal and often resist chemotherapy
BevCanna Enterprises launches Grüv Beverages, a range of CBD-infused iced tea drinks
The new line will be available initially in the US and in Canada following the legalization of infused products in October 2019
Circassia brings in top Pfizer exec as new chief operating officer
Jonathan Emms, who will officially join in September, arrives at a time when Circassia is transitioning into a more commercially-focused business
Benchmark Holdings hopeful string of licensing deals will offset ‘challenging’ shrimp and seabass markets
“The company is actively progressing its programme of operational and structural efficiencies, including key commercial licensing deals for its non-core animal vaccines, which, if completed this financial year, are expected to substantially
OptiBiotix continues to see commercial traction for its functional food technology
The latest deal involving its weight management productcovers Australia and New Zealand
Nemaura Medical boosts cash position in 1Q to launch SugarBeat in UK and other key European markets
The medtech company has a cash pile of $3,068,541 and an influx of cash in the form of an $8 million senior credit facility from its investors
IPO Roundup: AMTD International, InMode LTD each find their footing after going public
The two international companies are both up since they started trading in New York this week
Acasti Pharma reiterated as Speculative Buy by Mackie after FDA setback news for competitor Amarin
Amarin had recently indicated that they did not think they would need an FDA adcom meeting for their sNDA (supplemental new drug application) for Vascepa
IXICO says it is on track to meet market expectations as it gives an upbeat assessment of prospects
The company’s technology is used to interpret brain scans and is deployed by drug developers to aid with clinical trial
Next Green Wave says CEO and executive chairman Leigh Hughes resigns due to health, personal priorities, continues as advisor
Hughes commented: "I took over as CEO in January 2019 to lead NGW through a difficult formative period. NGW is now in a strong position to continue its growth cycle"
VolitionRx forms new Texas veterinary subsidiary, taps animal health expert Nathan Dewsbury to head it
Volition's NuQ diagnostic blood tests pinpoints irregular levels of nucleosomes in the blood, which indicate cancer
Propanc Biopharma moves closer to first-in-human study by quantifying ingredients for its metastatic cancer drug
This step allows Propanc to move forward in discussions with potential sites for its clinical trial, which the company expects to launch in early 2020
LexaGene to beta test its rapid pathogen detector at Assurance Scientific Laboratories
The company's LX Analyzer will test urine samples for pathogens and screen for antimicrobial resistance markers